2021
HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line
Stockhammer P, Okumus Ö, Hegedus L, Rittler D, Ploenes T, Herold T, Kalbourtzis S, Bankfalvi A, Sucker A, Kimmig R, Aigner C, Hegedus B. HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line. Pathology & Oncology Research 2021, 27: 636088. PMID: 34257602, PMCID: PMC8262245, DOI: 10.3389/pore.2021.636088.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinosarcomaCell Cycle CheckpointsCisplatinEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHistone DeacetylasesHumansMiddle AgedMutationPaclitaxelPhthalazinesPiperazinesPleural Effusion, MalignantPrognosisPyrazolesQuinolinesTumor Cells, CulturedUterine NeoplasmsVorinostatConceptsEpithelial-mesenchymal transitionUterine carcinosarcomaPleural effusionMesenchymal-epithelial transitionCell linesPatient-derived preclinical modelsMalignant pleural effusionMetastatic tumor lesionsVimentin-positive tumorsE-cadherinCarcinosarcoma cell lineInduces cell cycle arrestHistone deacetylase inhibitionFirst-line chemotherapeuticsΒ-catenin expressionE-cadherin expressionPSmad2 expressionCell cycle analysisPositive tumorsAggressive malignancyMetastatic tumorsDisease progressionCell cycle arrestNovel therapiesPreclinical models
2020
HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line
Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B, Theurer S, Hager T, Herold T, Kalbourtzis S, Bankfalvi A, Schmid KW, Führer D, Aigner C, Hegedűs B. HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line. Pathology & Oncology Research 2020, 26: 2523-2535. PMID: 32591993, PMCID: PMC7471186, DOI: 10.1007/s12253-020-00834-y.Peer-Reviewed Original ResearchConceptsPD-L1 expressionAnaplastic thyroid cancerPapillary thyroid cancerHDAC inhibitor treatmentThyroid cancerInhibitor treatmentHDAC inhibitionAdditional preclinical modelsAnaplastic thyroid cancer cell linesAnaplastic thyroid cancer cellsMalignant pleural effusionThyroid cancer cell linesNew therapeutic optionsThyroid cancer cellsCell linesCancer cell linesStandard chemotherapyFavorable prognosisMale patientsClinical outcomesNovel cell linePleural effusionTherapeutic optionsAggressive malignancyCell cycle arrestHDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model
Stockhammer P, Ho CSL, Hegedus L, Lotz G, Molnár E, Bankfalvi A, Herold T, Kalbourtzis S, Ploenes T, Eberhardt WEE, Schuler M, Aigner C, Schramm A, Hegedus B. HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. Lung Cancer 2020, 144: 20-29. PMID: 32353632, DOI: 10.1016/j.lungcan.2020.04.002.Peer-Reviewed Original ResearchConceptsALK tyrosine kinase inhibitorsCell linesALK fusion oncogeneDistinct resistance mutationsTreatment-naïve ALKMalignant pleural effusionPost-treatment tumorsLung cancer modelPan-HDAC inhibitorsNovel therapeutic approachesTyrosine kinase inhibitorsMesenchymal transition (EMT) markersLung adenocarcinoma modelTime of resistancePleural effusionALK inhibitionLung adenocarcinomaSubcutaneous xenograftsALK inhibitorsTherapeutic approachesCell line pairsCancer modelAdenocarcinoma modelHDAC inhibitionTransition markersTumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition
Ghanim B, Rosenmayr A, Stockhammer P, Vogl M, Celik A, Bas A, Kurul IC, Akyurek N, Varga A, Plönes T, Bankfalvi A, Hager T, Schuler M, Hackner K, Errhalt P, Scheed A, Seebacher G, Hegedus B, Stubenberger E, Aigner C. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition. Scientific Reports 2020, 10: 5784. PMID: 32238865, PMCID: PMC7113285, DOI: 10.1038/s41598-020-62813-2.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitionC-reactive proteinMalignant pleural effusionKi-67 indexPD-L1Overall survivalPleural effusionPrognostic powerPD-L1 tumor proportion scoreNegative PD-L1 statusPD-L1 positive tumorsLonger median OSMedian overall survivalPD-L1 expressionPD-L1 statusTumor proportion scoreFurther prospective validationVariety of malignanciesICI therapyMedian OSSignificant prognosticatorShorter OSIndependent prognosticatorPrognostic roleDismal prognosis
2019
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma
Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 2019, 139: 124-132. PMID: 31778960, DOI: 10.1016/j.lungcan.2019.11.013.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePleural effusionMPM patientsPleural mesotheliomaPrognostic stratificationNon-epithelioid malignant pleural mesotheliomaStage IV lung cancerEpithelioid malignant pleural mesotheliomaInferior overall survivalTGF-β levelsLevels of TGFLung cancer patientsChest CT scanOverall survivalSMRP levelsClinicopathological characteristicsDismal prognosisPleural diseaseTumor loadAggressive malignancyDisease stageCancer patientsLung cancerPrimary diagnosis1849P Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma
Stockhammer P, Ploenes T, Schuler M, Langer S, Aigner C, Hegedus B. 1849P Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma. Annals Of Oncology 2019, 30: v750-v751. DOI: 10.1093/annonc/mdz266.008.Peer-Reviewed Original ResearchMalignant pleural mesotheliomaNon-malignant pleural diseaseTGF-β levelsMPM patientsPleural mesotheliomaNon-epithelioid malignant pleural mesotheliomaMultivariate Cox regression modelWorse overall survivalCox regression modelFuture clinical trialsPleural effusion samplesAdvanced diseaseMultimodality treatmentOverall survivalDismal prognosisEpithelioid tumorsPleural effusionPleural diseaseAggressive malignancyClinical trialsPrognostic biomarkerPatientsReliable biomarkersEffusion samplesSignificant negative correlationPD-L1 and Ki67 are prognostic in malignant pleural effusion – a retrospective international multicenter study
Ghanim B, Rosenmayr A, Vogl M, Celik A, Bas A, Kurul I, Akyurek N, Varga A, Aigner C, Plönes T, Hegedüs B, Stockhammer P, Hackner K, Errhalt P, Scheed A, Seebacher G, Stubenberger E. PD-L1 and Ki67 are prognostic in malignant pleural effusion – a retrospective international multicenter study. Zentralblatt Für Chirurgie - Zeitschrift Für Allgemeine Viszeral- Thorax- Und Gefäßchirurgie 2019, 144: s92-s92. DOI: 10.1055/s-0039-1694203.Peer-Reviewed Original ResearchIn a Novel Malignant Pleural Effusion Derived Anaplastic Thyroid Cancer Line PD-L1 Expression is Strongly Increased by HDAC Inhibitor Treatment
Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B, Schmid K, Führer D, Aigner C, Hegedűs B. In a Novel Malignant Pleural Effusion Derived Anaplastic Thyroid Cancer Line PD-L1 Expression is Strongly Increased by HDAC Inhibitor Treatment. Pneumologie 2019, 73: 111-111. DOI: 10.1055/s-0039-1678390.Peer-Reviewed Original Research